HKEX: 3696
Voluntary announcement Insilico Medicine nominates next-generation small molecule gipr antagonist for potential intervention of obesity and related disorders
View original source (HKEXnews)
Earlier from Insilico Medicine Cayman Topco
- Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study
- Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
- Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
- Commercialization Roadmap Validated with Three-digit Million-dollar Revenue, Insilico Medicine Announces Interim Results for the First Half of 2026